- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.08. | HMNC recalibrates precision depression push after phase 2b miss, plans further development | ||
| 05.08. | Imunon puts COVID-19 vaccine on ice and seeks partner amid cash crunch | ||
| 05.08. | Pfizer's embattled obesity program loses another GLP-1 drug | ||
| 05.08. | BioMarin drops preclinical PKU drug once seen as potential Palynziq successor | ||
| 04.08. | Senate committee opposes Trump's NIH cuts, proposes $400M budget increase | ||
| 04.08. | OrbiMed gathers $1.86B for latest fund despite 'challenging' biotech equity market | ||
| 04.08. | Praxis links epilepsy drug to fall in seizures but sees 23% drop-out rate | ||
| 04.08. | Xoma goes shopping for struggling biotechs, picking up HilleVax and Lava | ||
| 04.08. | Skin-focused Sirona closes R&D labs as Allergan deal, financing plans collapse | ||
| 01.08. | Lepu Biopharma supplies two T-cell engagers to new company in $857M deal | ||
| 01.08. | Spine BioPharma misses primary endpoint in back pain phase 3, blames sham response rate | ||
| 01.08. | Sanofi pens $395M China pact for Arrowhead metabolic med awaiting approval decision | ||
| 01.08. | 4DMT's stock climbs as eye disease gene therapy patients keep jettisoning injections | ||
| 31.07. | Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test | ||
| 31.07. | AbbVie's IL-1 asset misses mark as monotherapy in phase 2 ulcerative colitis study | ||
| 31.07. | Nuvectis axes ovarian cancer program after seeing phase 1b data | ||
| 31.07. | Frazier Life Sciences raises $1.3B for latest early-stage biotech venture fund | ||
| 31.07. | AbbVie crowns Gilgamesh its next M&A target with $1B buyout talks: report | ||
| 30.07. | FDA misses IND deadline for Coya's ALS asset, cites lack of resources | ||
| 30.07. | Vyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stock | ||
| 30.07. | Madrigal pens $2B pact for CSPC's preclinical GLP-1 with eye on Rezdiffra MASH pairing | ||
| 30.07. | Investors whale on Cardiff, sinking stock after seeing updated colorectal cancer data | ||
| 30.07. | GSK's anti-TIM-3 antibody flunks phase 3 trial as anti-TIGIT failure costs $629M | ||
| 30.07. | Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market | ||
| 29.07. | Merck axes midstage asset from $1.9B Pandion buyout due to lack of clinical benefit |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .